GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Applied Molecular Transport Inc (NAS:AMTI) » Definitions » EV-to-EBIT

Applied Molecular Transport (Applied Molecular Transport) EV-to-EBIT : 0.09 (As of May. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Applied Molecular Transport EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Applied Molecular Transport's Enterprise Value is $-5.74 Mil. Applied Molecular Transport's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-63.49 Mil. Therefore, Applied Molecular Transport's EV-to-EBIT for today is 0.09.

The historical rank and industry rank for Applied Molecular Transport's EV-to-EBIT or its related term are showing as below:

AMTI' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.86   Med: 0   Max: 0.23
Current: 0.09

During the past 5 years, the highest EV-to-EBIT of Applied Molecular Transport was 0.23. The lowest was -31.86. And the median was 0.00.

AMTI's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 8.915 vs AMTI: 0.09

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Applied Molecular Transport's Enterprise Value for the quarter that ended in Sep. 2023 was $-10.33 Mil. Applied Molecular Transport's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-63.49 Mil. Applied Molecular Transport's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 614.67%.


Applied Molecular Transport EV-to-EBIT Historical Data

The historical data trend for Applied Molecular Transport's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied Molecular Transport EV-to-EBIT Chart

Applied Molecular Transport Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
- - -14.27 -4.17 0.07

Applied Molecular Transport Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.07 -0.06 0.13 0.16

Competitive Comparison of Applied Molecular Transport's EV-to-EBIT

For the Biotechnology subindustry, Applied Molecular Transport's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Applied Molecular Transport's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Applied Molecular Transport's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Applied Molecular Transport's EV-to-EBIT falls into.



Applied Molecular Transport EV-to-EBIT Calculation

Applied Molecular Transport's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-5.744/-63.494
=0.09

Applied Molecular Transport's current Enterprise Value is $-5.74 Mil.
Applied Molecular Transport's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-63.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Applied Molecular Transport  (NAS:AMTI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Applied Molecular Transport's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 ) =EBIT / Enterprise Value (Q: Sep. 2023 )
=-63.494/-10.3297205
=614.67 %

Applied Molecular Transport's Enterprise Value for the quarter that ended in Sep. 2023 was $-10.33 Mil.
Applied Molecular Transport's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-63.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Applied Molecular Transport EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Applied Molecular Transport's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Applied Molecular Transport (Applied Molecular Transport) Business Description

Traded in Other Exchanges
N/A
Address
450 East Jamie Court, South San Francisco, CA, USA, 94080
Applied Molecular Transport Inc is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Its proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of therapeutic payloads across the intestinal epithelium (IE) barrier. Its product candidate, AMT-101, is an oral IL-10 fusion protein that has been designed for active transport across the IE barrier into local GI tissue. IL-10 is a potent immunomodulatory cytokine that is known to be the master regulator of immune homeostasis, including within GI mucosal tissue.
Executives
Shawn Cross officer: Chief Financial Officer 1825 K STREET SUITE 510, WASHINGTON DC 20006
Mahmood Tahir Ph.d. director, officer: Chief Executive Officer 1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
Brandon Hants officer: VP, Finance & Bus. Ops. 1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
Douglas A. Rich officer: Chief Technical Officer C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR, WESTLAKE VILLAGE CA 91362
Bittoo Kanwar officer: Chief Medical Officer 1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
Mrsny Randall Ph.d. director, officer: Chief Scientific Officer 1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
Aaron Vandevender director 1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080
David Lamond director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Epiq Capital Group, Llc other: Managing member of 10% owner ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Chad Boeding other: CEO of Managing Member ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Charlene A. Banard director C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO CA 94080
John W Smither director C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Epq Llc Amt Ps other: Owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Amtc Ps other: Owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Amtb Ps 10 percent owner 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521

Applied Molecular Transport (Applied Molecular Transport) Headlines

From GuruFocus